Oncolytics Biotech Inc. (ONCY)

[Noodle2]

I'm hoping the headlines for Oncolytics reads like this one day:

"Incyte Cancer Immunotherapy Drug Is Object of Desire for Two Big Pharma Rivals"

Key words: "object of desire"

"The combination of two or immunotherapy drugs to treat cancer more effectively is the next big commercial opportunity."

If only ONCYF spiked on stories like this, but wait, there was one on March 16, 2017:

CALGARY, March 16, 2017 /PRNewswire/ - "Oncolytics Biotech® Inc. (Oncolytics or the Company) (ONC.TO) (ONCYF) today announced that cancer charity Myeloma UK launched MUK eleven, a first-of-its-kind immunotherapy trial that aims to modulate the immune system to target myeloma. The Phase 1b trial will study immuno-viral therapy, REOLYSIN® (pelareorep), in combination with Celgene Corporation's immunomodulatory drugs (IMiDs), Imnovid® (pomalidomide) or Revlimid® (lenalidomide), as a rescue treatment in relapsing myeloma patients."

Perhaps, Celgene has a desire for Oncolytics?